Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?

被引:6
作者
Ambrosy, Andrew P. [1 ,2 ]
Parzynski, Craig S. [3 ]
Friedman, Daniel J. [4 ,5 ]
Fudim, Marat [4 ,5 ]
Hernandez, Adrian F. [4 ,5 ]
Fonarow, Gregg C. [6 ]
Masoudi, Frederick A. [7 ]
Al-Khatib, Sana M. [4 ,5 ]
机构
[1] Permanente Med Grp Inc, Div Cardiol, 2238 Geary Blvd,8th Floor, San Francisco, CA 94114 USA
[2] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[3] Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[4] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA
[5] Duke Clin Res Inst, Durham, NC USA
[6] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Ronald Reagan UCLA Med Ctr, Div Cardiol, Los Angeles, CA 90024 USA
[7] Univ Colorado, Div Cardiol, Anschutz Med Campus, Aurora, CO USA
关键词
heart failure; hospitalization; defibrillators; implantable; treatment outcome; 2013 ACCF/AHA GUIDELINE; SUDDEN-DEATH; CLINICAL CHARACTERISTICS; VASOPRESSIN ANTAGONISM; DECLINING RISK; TASK-FORCE; MANAGEMENT; TOLVAPTAN; MORTALITY; ADMISSION;
D O I
10.1161/CIRCULATIONAHA.118.035627
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Landmark studies have demonstrated the safety and efficacy of implantable cardioverter-defibrillators (ICDs) in selected stable ambulatory patients with heart failure (HF) with a reduced ejection fraction receiving optimal medical therapy. It is not known whether a recent hospitalization for HF before ICD placement is associated with subsequent outcomes. METHODS: A post hoc analysis was performed of Medicare beneficiaries enrolled in the National Cardiovascular Data Registry's ICD Registry with a known diagnosis of HF and an ejection fraction = 35% underdoing a new ICD placement for primary prevention. Patients were grouped based on the timing of ICD placement from the last hospitalization for HF. The association between timing of ICD placement and outcomes was assessed by using multivariable logistic regression models. RESULTS: The final analytic cohort included 81 180 patients undergoing initial ICD placement for primary prevention who were currently hospitalized for HF (n= 11 563, 14%), hospitalized for HF within 3 months (n= 6252, 8%), or hospitalized for HF > 3 months previously or had no previous hospitalizations for HF (n= 63 365, 78%). Patients currently or recently hospitalized for HF had a higher unadjusted composite periprocedural complication rate (2.60% versus 1.71% versus 1.25%, P< 0.001). After adjusting for potential confounders, patients currently hospitalized for HF were at higher risk for death (odds ratio, 2.25; 95% CI, 2.02-2.52; P < 0.001) and all-cause readmission (odds ratio, 1.89; 95% CI, 1.79-1.99; P < 0.001) at 90 days. CONCLUSION: Older patients currently or recently hospitalized for HF undergoing initial ICD placement for primary prevention experienced a higher rate of periprocedural complications and were at increased risk of death in comparison with those receiving an ICD without recent HF hospitalization. Additional prospective, real-world, pragmatic, comparative effectiveness studies should be conducted to define the optimal timing of ICD placement.
引用
收藏
页码:2787 / 2797
页数:11
相关论文
共 50 条
  • [31] Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention
    Sarrias, Axel
    Galve, Enrique
    Sabate, Xavier
    Moya, Angel
    Anguera, Ignacio
    Nunez, Elaine
    Villuendas, Roger
    Alcalde, Oscar
    Garcia-Dorado, David
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (06): : 492 - 496
  • [32] Long-term clinical outcomes after placement of an implantable cardioverter-defibrillator: does the etiology of heart failure matter?
    Wasiak, Michal
    Tajstra, Mateusz
    Pyka, Lukasz
    Gasior, Mariusz
    KARDIOLOGIA POLSKA, 2020, 78 (04) : 318 - 324
  • [33] Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients
    Zhang, Yiyi
    Blasco-Colmenares, Elena
    Harms, Amy C.
    London, Barry
    Halder, Indrani
    Singh, Madhurmeet
    Dudley, Samuel C.
    Gutmann, Rebecca
    Guallar, Eliseo
    Hankemeier, Thomas
    Tomaselli, Gordon F.
    Cheng, Alan
    EUROPACE, 2016, 18 (09): : 1383 - 1390
  • [34] Depressive Symptoms and Quality of Life in Patients With Heart Failure and an Implantable Cardioverter-Defibrillator
    Zormpas, Christos
    Kahl, Kai G.
    Hohmann, Stephan
    Oswald, Hanno
    Stiel, Christopher
    Veltmann, Christian
    Bauersachs, Johann
    Duncker, David
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [35] Heart failure patients unresponsive to implantable cardioverter-defibrillator therapy: a neglected problem
    Disertori, Marcello
    Mase, Michela
    Rigoni, Marta
    Nollo, Giandomenico
    Ravelli, Flavia
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (12) : 1507 - 1509
  • [36] Diabetes Mellitus and Outcomes of Cardiac Resynchronization With Implantable Cardioverter-Defibrillator Therapy in Older Patients With Heart Failure
    Echouffo-Tcheugui, Justin B.
    Masoudi, Frederick A.
    Bao, Haikun
    Spatz, Erica S.
    Fonarow, Gregg C.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2016, 9 (08)
  • [37] Implantable Cardioverter-Defibrillator Therapy in the Contemporary Era of Heart Failure Therapeutics COMMENT
    Chatterjee, Neal A.
    Levy, Wayne C.
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2022, 8 (08) : 1031 - 1033
  • [38] Time to Shock the System: Moving Beyond the Current Paradigm for Primary Prevention Implantable Cardioverter-Defibrillator Use
    Merchant, Faisal M.
    Levy, Wayne C.
    Kramer, Daniel B.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (05):
  • [39] Are We Improving Care of Medicare Patients Undergoing Primary Prevention Implantable Cardioverter-Defibrillator Implantation?
    Russo, Andrea M.
    CIRCULATION, 2014, 130 (10) : 808 - 810
  • [40] Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention
    Reinder Evertz
    Tessa van der Heijden
    Rypko Beukema
    Sjoerd Westra
    Esther Meindersma
    Caroline van Deursen
    Kevin Vernooy
    Netherlands Heart Journal, 2023, 31 : 348 - 356